Edward M. Sellers, MD, PhD, FRCPC, FACP
President and Principal, DL Global Partners Inc.
An internationally recognized authority on clinical psychopharmacology, pharmacogenetics and smoking, abuse liability assessment and substance abuse.
has been active in basic and applied science for over 40 years.
During this time, he
has published more than 350 peer reviewed papers and has been cited more than 23,000 times.
has a broad base of experience as an academic, hospital and CRO industry executive.
has made not only pivotal scientific contributions but also, through his
leadership and ability to problem solve, has been instrumental in successfully building programs, units and businesses.
He is a founder of DecisionLine Clinical Research, Nicogen Inc. and ValleVista Natural Health Inc.
As an independent consultant he has worked with academic institutions, hospitals, government agencies, investors and biopharmaceutical and device companies achieving a deep understanding of their needs.
Areas of current focus include accelerating early stage drug development through new methods, optimizing strategies to assess abuse potential of new and re-formulated drugs and regulatory risk management and application of abuse liability methodology to modified risk tobacco related products.
After receiving his MD (Toronto 1965), PhD (Harvard 1971) and Internal Medicine specialty certification (1972), Dr. Sellers began his scientific career at the University of Toronto in 1972 and rapidly rose to the rank of full Professor as he established the world's foremost clinical psychopharmacology unit which trained many of today's leaders in the field.
During this period he also became responsible for the operations of the Clinical Institute of the Addiction Research Foundation, one of the world's largest and best known research and treatment organizations in the substance abuse field.
With increasingly senior appointments at the University of Toronto
, for a period of five years he
was responsible for all of the academic programs at the Faculty of Medicine University of Toronto
In 1997, he co-founded and served as President and CEO of DecisionLine Clinical Research Corporation which grew to be a world leading early stage CRO focused on CNS drug development with over 80 beds and 220 employees until acquired in 2008 by Kendle International.
In 2010, he founded DL Global Partners Inc.
He sits on numerous Scientific Advisory Boards of pharmaceutical and device companies and recently chaired the Scientific Advisory Panel on Opiate Analgesic Abuse for the Therapeutic Products Directorate, Health Canada.
has received numerous awards including the Rawls Palmer Progress in Medicine Award (1987 ASCPT); Nathan B. Eddy Award 2012 CPDD; Oscar B Hunter Award (2014 ASCPT).